Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lidocaine + estradiol
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Vaginal, Topical
01
Overview
A combination of lidocaine, a local anesthetic that blocks sodium channels to prevent pain signals, and estradiol, a naturally occurring estrogen hormone. This combination is primarily used to treat gynecological conditions in postmenopausal women, including vulvodynia, atrophic vaginitis, genital pain, and vaginal dryness. The lidocaine component provides pain relief while estradiol addresses hormonal deficiency symptoms.
02
Targets
NaV (Voltage-gated sodium channels)ESR1 (ERα)GPER1 (G protein-coupled estrogen receptor 1)ESR2 (ERβ)
Beyond the preview
Go deeper on lidocaine + estradiol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lidocaine + estradiol.